Search Results for: wto
Contrast in privilege: US officials working to block WTO LDC drug patent waiver, and people affected by policy
On the left, the people in the Obama Administration trying to block a permanent waiver of WTO drug patent obligations for Least Developed Countries (as defined by the UN). On the right, some people living in least developed countries.
 Ambassador Michael Forman. Head of USTR. Alma maters: Princeton, Oxford and Harvard Law. Formerly ran a hedge fund for Citibank. Continue Reading KEI protests USTR opposition to WTO LDC permanent drug patent waiverOn Wednesday, October 14, 2015, KEI staff and members of Public Citizen’s Global Access to Medicines team demonstrated outside of the White House and USTR, urging the administration, especially USTR and Ambassador Michael Froman, to support a request for a permanent drug patent waiver for Least Developed Countries (LDCs) at the WTO. Below are images from the protest action, also available in higher resolution here. And, yes, you can use these photos under any creative commons or wikimedia license. Commentary on the WTO negotiations over waiver of drug patents for Least Developed Countries (LDCs)Below you will find a collection of articles in the press and commentary by KEI relating to the request for LDC patent exemption on pharmaceutical products at the WTO. KEI commentary Senator Sherrod Brown letter to USTR, supporting permanent waiver of WTO drug patent rules for LDCsAttached is a letter, dated October 14, 2015, from Senator Sherrod Brown to USTR’s Ambassador Michael Froman, urging USTR to support a permanent waiver of WTO drug patent rules, for Least Developed Countries. Negotiations on this issue begin formally on October 15, 2015, during a meeting of the WTO TRIPS Council. Among the money quotes: WTO TRIPS Council (October 2015) to discuss LDC extension for pharmaceuticals, non-violation, review of the Paragraph 6 systemThe WTO TRIPS Council meets from Thursday, 15 October 2015 to Friday, 16 October 2015. The hot topics for consideration include agenda item 13 (Request from the LDC Group for an indefinite exemption from WTO IP obligations to provide patents for pharmaceutical products, agenda item 8 (non-violation and situation complaints), agenda item 7 (Review of the Paragraph 6 system) and agenda item 14 (a discussion item co-sponsored by Australia, the European Union and the United States on “Intellectual Property and Innovation: Entrepreneurialism and New Technologies).
|